Baloxavir: Mechanism of Action, Indications and Important Notes
Baloxavir marboxil is an antiviral active substance used for the treatment of influenza (flu). The active substance belongs to a new class of antivirals and differs fundamentally in its mechanism of action from older antiviral influenza medications such as oseltamivir. Baloxavir was first approved in Japan and has been available in various countries including the United States since 2018. In Europe, marketing authorisation was extended in subsequent years.
Influenza is an acute respiratory disease caused by influenza viruses (types A and B), which leads to seasonal epidemics particularly during the winter months. In most healthy people, influenza is self-limiting, but can lead to serious complications in certain risk groups such as older people, immunocompromised individuals and those with underlying conditions.
Mechanism of Action
Baloxavir marboxil is a prodrug: after oral administration, it is rapidly converted in the body to the active metabolite baloxavir. This specifically inhibits an enzyme of the influenza virus called cap-dependent endonuclease, which is part of the viral polymerase complex (PA subunit of the polymerase acidic protein). This enzyme is essential for the replication of the influenza virus: it hijacks cellular messenger RNA structures (cap-snatching mechanism) to initiate the synthesis of viral mRNA. Without this step, the virus cannot produce new proteins and cannot multiply.
This mechanism of action fundamentally distinguishes baloxavir from neuraminidase inhibitors such as oseltamivir, which block the release of newly formed viruses from infected cells. Because baloxavir targets a different step in the viral lifecycle, there is no cross-resistance between baloxavir and oseltamivir. Baloxavir is active against influenza virus A and B, including oseltamivir-resistant strains and against avian influenza types in laboratory experimental investigations.
Indications
Treatment of Uncomplicated Influenza
Baloxavir is approved for the treatment of uncomplicated influenza in patients above a certain age and body weight, depending on national authorisation. The active substance is particularly effective when taken early after symptom onset. Clinical studies show that baloxavir can shorten the duration of symptoms. For greatest efficacy, intake should occur within the first 48 hours after symptom onset.
High-Risk Patients
Baloxavir is also used in patients at increased risk of influenza complications, for example in older patients, immunocompromised individuals, or patients with certain underlying conditions such as asthma, heart disease or diabetes mellitus. In these groups, antiviral therapy can favourably influence the course of the disease and reduce serious complications.
Single-Dose Concept
A significant practical advantage of baloxavir is that it is generally taken as a single dose. This greatly simplifies therapy compared to oseltamivir, which must be taken twice daily over five days. A single dose can improve treatment adherence and is particularly advantageous for patient groups in whom therapy taken multiple times daily is difficult to implement.
Dosage Form and Dosing
Baloxavir is available as film-coated tablets. Dosing is based on body weight: for patients weighing less than 80 kg, 40 mg as a single dose is recommended; for patients weighing 80 kg or more, 80 mg as a single dose. Tablets should not be taken together with milk, dairy products or calcium-containing dietary supplements, as calcium can impair absorption of baloxavir. Antacids containing magnesium, aluminium or calcium should also not be taken simultaneously.
Important Notes
Baloxavir is not a substitute for annual influenza vaccination. Vaccination is the most effective measure for preventing influenza and is recommended by health authorities especially for risk groups. Antiviral therapy with baloxavir is a supplementary measure for the treatment of an already established illness.
Intake should occur as early as possible after the onset of influenza symptoms, as antiviral efficacy decreases with increasing duration of illness. Rapid medical assessment is therefore advisable when influenza is suspected.
Resistance Development
Under baloxavir therapy, variants of the influenza virus with reduced susceptibility to the active substance have been described. These so-called PA-I38T/A/M variants arise through mutations in the PA subunit of the viral polymerase complex. The clinical significance of these variants is being investigated in ongoing studies. In patients with a weakened immune system in whom viral replication persists longer, the risk of resistance development may be increased.
Adverse Effects
Baloxavir is generally well tolerated. Possible adverse effects include:
- Diarrhoea, which is common and usually mild
- Nausea
- Bronchitis in patients with underlying respiratory disease
- Headache
- Very rarely: allergic reactions
- Rare reports of behavioural disorders, particularly in children and adolescents, have also been described for other antiviral influenza medications
Drug Interactions
Polyvalent cations such as calcium, magnesium, aluminium and iron can significantly reduce the absorption of baloxavir. Therefore, baloxavir should not be taken together with antacids, dairy products, dietary supplements or certain other preparations containing such ions. A gap of at least a few hours from the intake of baloxavir should be maintained.
Vaccination and Antiviral Therapy
Annual influenza vaccination remains the most important measure for preventing flu. Antiviral agents such as baloxavir complement vaccination but do not replace it. Vaccination should ideally be carried out before the start of the flu season, typically in autumn. Health authorities explicitly recommend vaccination for certain risk groups. For medical and nursing staff, influenza vaccination is also relevant for patient protection reasons.
The simultaneous availability of various antiviral agents is important for the treatment of influenza patients in whom resistance to one agent is present. Because baloxavir and oseltamivir act at different target sites of the virus and show no cross-resistance, they can be combined when necessary. This is particularly the subject of clinical research in immunocompromised patients with severe influenza.
Baloxavir on Sanoliste
On Sanoliste you will find general practitioners, internists and pulmonologists who offer qualified diagnostics and counselling for respiratory conditions including influenza. Early medical assessment is especially important for risk groups in order to initiate antiviral therapy in time and prevent complications.
The content on this page is for informational purposes only and does not replace medical consultation. Baloxavir is a prescription-only medicine.
Frequently Asked Questions about Baloxavir
How does baloxavir differ from oseltamivir?
Baloxavir and oseltamivir are both antiviral agents against influenza, but differ fundamentally in their target. Oseltamivir inhibits the neuraminidase of the virus, thereby preventing the release of newly formed viruses from infected cells. Baloxavir, on the other hand, blocks the cap-dependent endonuclease and interrupts the synthesis of viral proteins directly at the start of replication. Another key difference lies in dosing: baloxavir is taken once, oseltamivir twice daily over five days. Since there is no cross-resistance, baloxavir is also effective against oseltamivir-resistant influenza strains.
Can baloxavir also be used preventively?
The authorisation of baloxavir primarily concerns the treatment of influenza. For post-exposure prophylaxis, i.e. preventive intake after close contact with an infected person, baloxavir has been used and investigated in certain situations in some countries. Whether and in what situation a prophylactic intake is appropriate is decided by the treating physician on a case-by-case basis, taking into account national guidelines.
Is baloxavir also suitable for children?
The authorisation includes children from a certain age and body weight depending on the country. In Japan and the United States, baloxavir is also approved for younger children. In Europe, the precise age authorisation depends on the respective national authority. The treating paediatrician or paediatric infectiologist provides information on whether baloxavir is appropriate for a specific child.